A Different Way of Looking at the “Why?” Questions Around Glioblastoma (UK)

In UK brain tumour groups, the same questions come up again and again:

• Why is there so little funding?

• Why are new treatments so slow?

• Why are some treatments available abroad but not on the NHS?

• Why does care sometimes feel like a postcode lottery?

These are completely understandable questions. When time feels precious, delays feel unbearable.

I’ve personally received excellent care and feel very grateful. But I’ve also been wondering whether some of the delays are more about biology and systems than politics alone.

1. Glioblastoma is extremely hard to treat

This isn’t just a case of “not enough funding.”

Glioblastoma is very complex. Tumours can behave differently even when they look the same. They change during treatment. The blood–brain barrier blocks many drugs from reaching the tumour. And what works for one patient may not work for another.

Around the world, many large clinical trials have failed to significantly extend survival. That shows how scientifically difficult this disease is.

That doesn’t make it less urgent. But it helps explain why progress has been slow.

2. Approval and NHS funding are different things

In the UK, a drug must first be approved as safe and effective. Then it has to be assessed for value for money before the NHS can routinely fund it. This is done by bodies like the National Institute for Health and Care Excellence.

The NHS doesn’t set drug prices — pharmaceutical companies do.

When we hear that something is “available abroad,” it’s often:

• Only available privately

• Part of a clinical trial

• Approved based on early data

That doesn’t mean the system is perfect. But it’s more complicated than simple refusal.

3. Numbers and economics matter

About 3,500 people are diagnosed with glioblastoma each year in the UK. It’s devastating — but statistically a small group.

Developing drugs is expensive and risky, especially after many failed trials. That affects investment.

4. The postcode issue

Big specialist centres are more likely to run trials and offer advanced testing. That can create real regional differences — often because of staffing and research capacity, not because doctors are withholding care.

Frustration and anger are completely understandable.

But if the barriers are partly biological and partly structural, maybe the question becomes:

Where should we focus our energy to create real change?

I’d genuinely value hearing how others see this.